Global drugmakers ready to use dumping to get better access to Russian pharma market

3 December 2019

Global drugmakers will continue to the use the policy of dumping in the Russian pharmaceutical market in years to come, in an attempt to get a better access to public procurements in Russia, according to recent statements by some local analysts in the field of pharmaceuticals and senior officials of the Russian Ministry of Health, reports The Pharma Letter’s local correspondent.

According to analysts, an example of this is a recent proposal sent to the Russian government by the British pharma major GlaxoSmithKline (LSE: GSK) sent to the Ministry of Health, which promised to reduce price for its dolutegravir, a treatment for HIV marketed as Tivicay, by almost 27%.

In exchange, the company hopes to take part in tenders that will involve purchases of the drug for the needs of the Russian government.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK